The Challenge of Finding a Cure for HIV Infection
Top Cited Papers
- 6 March 2009
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 323 (5919) , 1304-1307
- https://doi.org/10.1126/science.1165706
Abstract
Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4 + lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.Keywords
This publication has 46 references indexed in Scilit:
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 2008
- Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT MicePLoS Medicine, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latencyThe EMBO Journal, 2007
- c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 PromoterJournal of Virology, 2007
- HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTRBMC Molecular Biology, 2007
- Regulation of HIV-1 latency by T-cell activationCytokine, 2007
- Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 + T CellsJournal of Virology, 2006
- Hexamethylbisacetamide Remodels the Human Immunodeficiency Virus Type 1 (HIV-1) Promoter and Induces Tat-Independent HIV-1 Expression but Blunts Cell ActivationJournal of Virology, 2006
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997